Terran Biosciences is a biotech platform company devoted to the development of transformative therapeutics and technologies for patients with neurological and psychiatric diseases.
Our portfolio includes a late-stage therapy for schizophrenia, late-stage selective serotonin 2A receptor antagonists, a drug design engine that has enabled first-in-class and best-in-class psychedelic therapies, and an AI-enabled imaging software platform.
Our team consists of biopharma industry professionals and successful physician-entrepreneurs, and we are uniquely positioned to become a leader in the rapidly growing renaissance in neuroscience.
Terran’s pipeline includes several innovative late-stage assets, each with the potential to transform the paradigm in patient care
Idazoxan XR
A novel alpha 2 adrenergic receptor antagonist for the treatment of schizophrenia and Alzheimer’s disease, which has been tested in several late-stage clinical studies and dosed in over 1000 patients. Phase 2 proof of concept studies have already demonstrated significant efficacy as adjunctive therapy in patients with schizophrenia. Terran has created a novel enantiomerically pure extended-release version of the drug (“Idazoxan XR”) that can be dosed once-daily, solving the pharmacokinetic challenges that historically required 3-4 daily doses.
Phase 3 selective serotonin 2A receptor antagonists for the treatment of various neuropsychiatric illnesses. Tested in over 15,000 patients across more than 100 clinical trials, Terran is developing fixed-dose combinations of these compound with psychedelics with the goal of removing hallucinations while maintaining efficacy. Monotherapy applications include Parkinson’s psychosis and tailoring psychedelic effects to a desired duration or ending bad psychedelic experiences all together. Exclusively licensed from Sanofi, Terran holds global development and commercialization rights. Terran has also acquired novel deuterated volinanserin from Concert Pharmaceuticals.
Psychedelics and Empathogens
Terran has one of the largest psychedelic development programs in the industry, including psychedelics with a long history of human use, such as psilocybin, LSD, DOM, 2C-B, the empathogens MDMA and its derivatives (MDEA, methylone, MDAI, MBDB, MDA). Terran has also developed novel psychedelic prodrugs (psilocin, LSD, 2C-B, methylone, long-acting MDMA, orally-active DMT and 5-MeO-DMT)as well as improved psychoplastogens (non-hallucinogenic derivatives of DMT and ibogaine), and therapeutics without effects at the 5-HT2B receptor. Terran is also a leader in the manufacturing of GMP psychedelic compounds and is actively supplying researchers and treatment centers globally.
Terran’s world-class medicinal chemistry and drug design team is working to solve some of the biggest problems in neuroscience and remove the limitations that affect otherwise highly effective compounds.
We have designed innovative novel compounds, new synthetic routes, prodrugs and stable labeled compounds with improved pharmacokinetic properties, as well as compounds with modified binding at target receptors, including the removal of binding at targets deemed to be potential liabilities.
In partnership with Columbia University, we have developed an AI-enabled imaging software platform to facilitate the automated measurement of neuromelanin, a dopamine breakdown product and a well-known biomarker in Parkinson’s disease and other neuropsychiatric conditions.
This technology has been tested in hundreds of patients across a number of indications, and we have made this technology available for collaboration with universities, treatment centers, and other industry partners. Please reach out to us to learn more.
Sam Clark, MD, PhD
Chief Executive Officer
Dustin Tetzl, MD
Chief Business Officer
Annette Madrid, MD
Head of Clinical Research
Matt Duncton, PhD
Senior Director, Medicinal Chemistry
Lucia Johnson
Director, Strategy & Operations
Marine Yamada
Senior Manager, Strategy & Operations
Kim Stahl
Clinical Operations Lead
Steve Smith
DMPK Lead
Mamta Hunt
Data Management
James Bernstein, PhD
CMC lead
Grace Jung, PhD
CMC, Process Chemistry
Vassil Elitzin, PhD
CMC, Process Chemistry
Roy Swaringen, PhD
CMC, Process Chemistry
Ruxandra Lonescu, PhD
CMC, Process Chemistry
Gary Goodson
CMC, Formulation Lead
Joe Chau, PhD
Quality Assurance
Cynthia Gronostajki
Quality Assurance
Ann Newman, PhD
Solid State Chemistry
Bram Lardee
CMC, Analytical Development
Elizabeth Steere
CMC, Analytical Development
Elina Kolosovsky-Simberg
CMC, Analytical development
Charles M. Beasley Jr., MD
Clinical Advisor
Jerry Rosenbaum, MD
Harvard, Mass. General, Psychiatrist-in-Chief emeritus; Director, Center for Neuroscience of Psychedelics
Robert Litman, MD
Georgetown Univ., Associate Prof. of Psychiatry; Medical Director and PI at CenExel CBH
